SCHEMBL222418

SCHEMBL222418

C#Cc1ccccc1[C@@H](C[N+](=O)[O-])C(C(=O)c1ccccc1)C(=O)c1ccccc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CPA1 P15085 3/20 0.37
ALDH1A1 P00352 5/20 0.36
CYP3A4 P08684 1/20 0.36
CYP1A2 P05177 2/20 0.33
TSHR P16473 1/20 0.32
MDM2 Q00987 1/20 0.32
HTT P42858 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
CES2 O00748 2/20 0.31
CES1 P23141 2/20 0.31
CNR1 P21554 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
NPC1 O15118 1/20 0.31
ADAM17 P78536 1/20 0.31
CA12 O43570 1/20 0.30
CA1 P00915 1/20 0.30
CA2 P00918 1/20 0.30
CA9 Q16790 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL220307 0.80 CYP1A2 (0.51) CPA1ALDH1A1CYP1A2TSHRHTT
SCHEMBL220308 0.80 CYP1A2 (0.51) CPA1ALDH1A1CYP1A2TSHRHTT
SCHEMBL2760491 0.79 MDM2 (0.33) TSHRMDM2HTTCES2CES1
SCHEMBL221352 0.79 TDP1 (0.47) CPA1ALDH1A1CYP3A4MDM2HTT
SCHEMBL221353 0.79 TDP1 (0.47) CPA1ALDH1A1CYP3A4MDM2HTT
SCHEMBL222290 0.78 NPSR1 (0.48) CPA1ALDH1A1HTTMEN1KMT2A
SCHEMBL220493 0.78 CTNNB1 (0.45) CPA1ALDH1A1CYP3A4CYP1A2HTT
SCHEMBL222291 0.78 NPSR1 (0.48) CPA1ALDH1A1HTTMEN1KMT2A
SCHEMBL220492 0.78 CTNNB1 (0.45) CPA1ALDH1A1CYP3A4CYP1A2HTT
SCHEMBL6249908 0.74 CPA1 (0.46) CPA1ALDH1A1CYP3A4MDM2CES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8940938-B2 Michael reaction with recovery of the catalyst NANYANG TECHNOLOGICAL UNIVERSITY (SG) 2015-01-27 US disclosed
US-8940938-B2 Michael reaction with recovery of the catalyst NANYANG TECHNOLOGICAL UNIVERSITY (SG) 2015-01-27 US disclosed
US-8940938-B2 Michael reaction with recovery of the catalyst NANYANG TECHNOLOGICAL UNIVERSITY (SG) 2015-01-27 US disclosed
US-20120004424-A1 MICHAEL REACTION WITH RECOVERY OF THE CATALYST NANYANG TECHNOLOGICAL UNIVERSITY (SG) 2012-01-05 US disclosed
US-20120004424-A1 MICHAEL REACTION WITH RECOVERY OF THE CATALYST NANYANG TECHNOLOGICAL UNIVERSITY (SG) 2012-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004424-A1 MICHAEL REACTION WITH RECOVERY OF THE CATALYST CYP2E1, CYP11B2, CYP11B1 CPA1 3043/4885ALDH1A1 118/4885CYP3A4 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.